
Please try another search
BRUSSELS (Reuters) - EU antitrust regulators will decide by Dec. 7 whether to clear U.S. medical device company Thermo Fisher Scientific (NYSE:TMO)'s $21 billion bid for contract research firm PPD (NASDAQ:PPD) Inc, a European Commission filing showed on Wednesday.
Thermo Fisher, the world's largest maker of scientific instruments, announced the deal in April. The contract research industry is rebounding from pandemic disruption amid growing demand for virtual clinical trials.
The European Commission can clear the deal with or without concessions at the end of its preliminary review or it can open a four-month long investigation if it has serious concerns.
LONDON (Reuters) - Sterling plunged to a new March 2020 low against the dollar on Tuesday, extending losses after the resignation of Britain's finance minister threw Prime...
NEW YORK (Reuters) - A U.S. appeals court on Tuesday struck down an order by the Securities and Exchange Commission that would have allowed some financial firms that are not stock...
By Jonathan Stempel NEW YORK (Reuters) - A former managing director at Archegos Capital Management LP has sued the private investment firm and its indicted founder Bill Hwang,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.